MicroRNAs and Multiple Sclerosis

Table 2

Differential miRNA expression in Multiple Sclerosis.

Sampe type	Number of patients and disease status	Specificity of patients and treatment	Number of tested miRNA	Results	Target genes	Reference
Whole bood	59 MS (18 PP, 17 SP, 24 RR) and 37 controls	Causian No IMT	733	miR-17 and miR-20a downregulated	ND	Cox
CD4+CD25+	12 MS (RR) and 14 controls	No IMT	723	miR-106b, MiR-19a, MiR-19b and miR-25 upregulated	TGF β signaling	De Santis
CD4+, CD8+, B	8 MS (RR) and 10 controls (microarray)	No IMT	365	miR-17-5p upregulated in CD4+ cells	ND	Lindberg
	15 MS (RR)
	and 10 controls (qPCR)
Peripheral blood leukocytes	43 MS (RR)	Chinese	ND	miR 326 upreguated in CD4+ cells	Ets-1	Du
	40 control			miR-326 promotes Th-17 differentiation
	11 NMO
Whole bood	20 MS (RR)	glatiramer acetate (9)	866	miR-145 upregulated in MS	ND	Keller
	19 controls	interferon-b (10)
Whole bood	21 MS (9 remission, 4 relaps)	ND	364	miR-18b and miR-599 upregulated in relapse	interleukine signaling	Otaegui
	8 control			miR-96 upregulated in remission	Wnt, glutamate
Brain tissue	20 MS (16 active, 5 inactive)	ND	365	miR-34a, miR-155 and miR-326 upregulated in active lesions	CD47	Junker
	9 controls

Ets-1: v-ets erythroblastosis virus E26 oncogene homolog 1; IMT: Immunmodulatory treatment; MS: Multiple sclerosis; ND: not determined; NMO: neuromyeliis optica; PP: primary progressive; RR: Relapsing remitting, Secondary progressive.